Detecting anthrax proteins at ultralow concentrationsAugust 29, 2005A new laboratory method for quickly detecting active anthrax proteins within an infected blood sample at extremely low levels has been developed by researchers at the National Institute of Standards and Technology (NIST), the U.S. Army Medical Research Institute of Infectious Diseases and the National Cancer Institute. Current detection methods rely on injecting live animals or cell cultures with samples for analysis and require up to several days before results are available. Described* in an upcoming issue of the Journal of Biological Chemistry, the new method produces unambiguous results in about an hour. The researchers hope the system will ultimately be useful in developing fast, reliable ways to diagnose anthrax infections or to quickly screen large numbers of drugs as possible therapies for blocking the bacteria's toxic effects. The method works by detecting changes in current flow when anthrax proteins are present in a solution. An anthrax protein ironically called "protective antigen" spontaneously forms nanometer-scale pores that penetrate the surface of an organic membrane. When a voltage is applied across the membrane, positively and negatively charged ions flow freely in both directions through the pore. When additional anthrax proteins called lethal factor (LF) or edema factor (EF) are present, however, the proteins bind to the outside of the pore and shut down the flow of ions in one direction. This change in current flow depends on the concentration of the proteins in the solution and can detect amounts as low as 10 picomolar (trillionths of a mole).
"We hope this system will lead to a method for rapidly screening agents that inhibit the binding of LF or EF to these pores," says NIST's lead investigator John Kasianowicz. Live anthrax antibodies seem to do exactly that. When antibodies were present in the test solution and then LF was added, the current flow remained unchanged, indicating that the anthrax proteins were unable to bind properly. The long-term goal would be to find drugs with few side effects that also interfere with this binding process. National Institute of Standards and Technology (NI | |||||||||||||||||||||
|
Related Anthrax Current Events and Anthrax News Articles Scientists Present 'Moving' Theory Behind Bacterial Decision-Making Biochemists at North Carolina State University have answered a fundamental question of how important bacterial proteins make life-and-death decisions that allow them to function, a finding that could provide a new target for drugs to disrupt bacterial decision-making processes and related diseases. Scripps research scientists identify blood component that turns bacteria virulent Scientists from the Scripps Research Institute have discovered the key chemical that signals Bacillus anthracis, the bacterium that causes anthrax, to become lethal. This finding opens up new avenues of exploration for the development of treatments for bacterial infections. Nature study demonstrates that bacterial clotting depends on clustering Bacteria can directly cause human blood and plasma to clot-a process that was previously thought to have been lost during the course of vertebrate evolution, according to new research at the University of Chicago, National Institute of Allergy and Infectious Diseases, and Institut Pasteur in Paris. Their findings will be published online Nov. 2 in Nature Chemical Biology. UCLA develops safer, more effective TB vaccine for HIV-positive people UCLA scientists engineered a new tuberculosis (TB) vaccine specifically designed for HIV-positive people that was shown to be safer and more potent than the current TB vaccine in preclinical trials. Green catalysts provide promise for cleaning toxins and pollutants Tetra-Amido Macrocyclic Ligands (TAMLs) are environmentally friendly catalysts with a host of applications for reducing and cleaning up pollutants, and a prime example of "green chemistry." Carnegie Mellon University's Terry Collins, the catalyst's inventor, believes that the small-molecule catalysts have the potential to be even more effective than previously proven. Nano vaccine for hepatitis B shows promise for third world Chronic hepatitis B infects 400 million people worldwide, many of them children. Even with three effective vaccines available, hepatitis B remains a stubborn, unrelenting health problem, especially in Africa and other developing areas. Francisella tularensis: Stopping a biological weapon Scientists hope a vaccine is on the horizon for tularemia, a fatal disease caused by the pathogen Francisella tularensis, an organism of concern as a potential biological warfare agent. Until recently we knew very little about this bacterium. Effective health messages may yield vaccine compliance among ER workers Emergency room workers will be the first line of defense in the event of a disease pandemic and will be forced to deal with the chaos that inevitably comes with treating thousands of sick and dying. In order to protect themselves and allow them to care for the public, these first responders need to be fully prepared by getting available vaccines now. Tests show LLNL detection instrument can monitor the air for all major terrorist threat substances Security and law enforcement officials may some day have a new ally - a universal detection system that can monitor the air for virtually all of the major threat agents that could be used by terrorists. New strategies against bird flu The Spanish flu outbreak of 1918 killed between 30 and 50 million people. In the infected patients, the ultimate cause of death was acute respiratory distress syndrome (ARDS). More Anthrax Current Events and Anthrax News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||